Global Titans Brings the World’s First NFT Pay-Per-View Sports Event Live From the Helipad of Burj Al Arab, on May 14th, 2022
25.4.2022 17:40:00 EEST | Business Wire | Press release
ROQUMedia:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005564/en/
Mayweather Global Titans Poster (Photo: AETOSWire)
FLOYD MAYWEATHER:
https://twitter.com/FloydMayweather/status/1517594581373648896?s=20&t=dEEnqLrQWsybIa81CA-JJA
Global Titans Fight Series announced the WORLD’S FIRST EVER NFT SPORTS event will give access to an exclusive livestream pay-per-view for NFT ticket holders. The Global Titans NFT tickets are considered a historic moment, where sports and tech fans take a giant leap forward, changing the way one interacts with live entertainment.
The NFT ticket will give access to watch Global Titans Dubai live online on May 14th, where an epic night of boxing on the helipad of the iconic Burj Al Arab Jumeirah hotel. The spectacular event boasts an explosive line-up including star champions Floyd Mayweather, Anderson Silva and many more.
A landmark moment for international sports, fans buying the NFT will also acquire a special Global Titans NFT ticket, that is highly collectable. More than an event ticket, NFT technology provides buyers with unique features such as future access, rewards and more – all that increase the value of its ownership long after the event.
Developing special technologies, ROQUMedia and Yakomoz Events, the founders of Global Titans, have teamed up with Web3 experts, MintGate for this NFT. Buyers will be able to watch the livestream of these inaugural fights directly from anywhere in the world without requiring access codes or passwords. NFT owners can simply connect their crypto wallets (such as MetaMask) for instant access.
Additionally, owners of this NFT will be able to unlock Limited Edition 3D collectibles, special video content and official media from the event.
There are two Global Titans NFT tickets now available to the public.
- 80,000 collectible NFTs with PPV access in the Polygon Matic or payable by credit card.
- Currently 10 highly exclusive ringside seat NFTs are available to attend this event in person.
Seat to attend the event and collectable NFT ticket Pay-Per-View livestream are available at www.globaltitans.com
“MintGate is hyper-focused on making digital ownership accessible to anyone in the world,” said Jonathan Dunlap (CEO). “To further this mission, we launched a revolutionary way to purchase a NFT directly with a credit card,” continued Matt Hoffman (CSO).
Robert Quirke, ROQUMedia (CEO) stated: “For many people, this will be the first time they will buy an NFT. We made sure to provide them with great value, by including exciting digital assets that can be traded and combined to watch the Floyd Mayweather fight livestream online. The live event on May 14th will be known as an international turning point where live sports and entertainment embraced the next generation of technology. The PPV tickets use the Polygon Blockchain & MATIC, as this offers fans the lowest gas fees, making them significantly more environmentally friendly.”
GLOBAL TITANS
Global Titans Dubai is the first in series of special boxing and MMA events which will be staged at iconic locations across four continents. Each main event is broadcast globally, featuring champion fighters and exclusive collectable NFT tickets.
Seat to attend the event and collectable NFT ticket Pay-Per-View livestream: www.globaltitans.com
MINTGATE
MintGate is a proven web3 platform for building membership-based communities and elevating the relationship between people and the brands they care about. We bring people closer to the future by unlocking the value of digital ownership.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005564/en/
Contact information
KATCH INTERNATIONAL
Sharanya Paulraj
Email:
sharanya@katchthis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom